BOSTON, April 28, 2025--nChroma Bio ("nChroma"), a genetic medicines company advancing programmable in vivo delivery to overcome the limitations of existing therapies, today announced the acceptance ...

Data support potential of innovative gene therapy using novel RNA editing, paired with targeted AAV.ai delivery and scalable ...

A copy of the presentation materials will be added to the " Publications ” section of the Company's website at tscan.com once the presentation has concluded. About TScan Therapeutics, Inc.

Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, today announced that Co-Founder ...

"The excellent survival responses reported in patients with different tumor types in the Phase 2 study is very exciting, and ...

Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week ® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...

ATT-01 uses its ATTimmune platform technology, a silica-based, biodegradable scaffold (mesoporous silica rod, MSR), loaded with GM-CSF and CpG to induce differentiation of AML blasts in vitro, a ...

Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL®, and new data in treating V ...

The Undergraduate Research Symposium was held on Thursday at the Illini Union displaying research by students from all disciplines.

According to experts, these finds could be worth serious cash. From mid-century modern furniture and ceramics to vintage ...

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find ...